Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AKCA

Akcea Therapeutics (AKCA) Stock Price, News & Analysis

Akcea Therapeutics logo

About Akcea Therapeutics Stock (NASDAQ:AKCA)

Advanced Chart

Key Stats

Today's Range
$18.17
$18.17
50-Day Range
$18.13
$18.17
52-Week Range
$8.00
$21.70
Volume
N/A
Average Volume
361,806 shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AKCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akcea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AKCA Stock News Headlines

Arcturus Therapeutics Holdings Inc ARCT
AKCA Historical Data
2013 Bitcoin miner reveals his trading system (free)
While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematically extracting profits from the $4 billion that changes hands in crypto every single day.tc pixel
Akcea Therapeutics Inc (AKCA)
See More Headlines

AKCA Stock Analysis - Frequently Asked Questions

Akcea Therapeutics, Inc. (NASDAQ:AKCA) posted its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.14. The company's revenue for the quarter was down 15.9% compared to the same quarter last year.

Akcea Therapeutics (AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Advanced Micro Devices (AMD), Ciena (CIEN), Fossil Group (FOSL) and AMC Entertainment (AMC).

Company Calendar

Last Earnings
8/04/2020
Today
9/15/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKCA
CIK
1662524
Fax
N/A
Employees
248
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$0.48
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$40.77 million
Net Margins
-12.34%
Pretax Margin
N/A
Return on Equity
-8.94%
Return on Assets
-8.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.17
Quick Ratio
11.78

Sales & Book Value

Annual Sales
$488.54 million
Price / Sales
3.78
Cash Flow
$0.51 per share
Price / Cash Flow
35.54
Book Value
$5.78 per share
Price / Book
3.14

Miscellaneous

Outstanding Shares
101,599,000
Free Float
N/A
Market Cap
$1.85 billion
Optionable
Optionable
Beta
1.45
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:AKCA) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners